TrialLancet (London, England)2022

Efficacy, safety, and immunogenicity of the DNA SARS-CoV-2 vaccine (ZyCoV-D): the interim efficacy results of a phase 3, randomised, double-blind, placebo-controlled study in India.

Akash Khobragade et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.